Stock listing
Lang & Schwarz:A3EE5F Gyre Therapeutics, Inc. Aktie
German listing (Lang & Schwarz) of Gyre Therapeutics, Inc. · home listing NASDAQ:GYRE
Follow Gyre Therapeutics, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:GYRE
$4.44 USD -0.29 (-6.1%)
Close on Nov 3, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:GYRE
- Day range
- $4.40 – $4.71 USDNov 3, 2026
- Volume
- 239,505 sharesNov 3, 2026
- Market cap
- $470.8M USDAt the close on Nov 3, 2026 · price × 106.0M shares outstanding
- 52-week range
- $4.27 – $9.14 USDLowest and highest trades, Nov 4, 2025 – Nov 3, 2026
- Traded on an average day
- $895,570 USDMedian day 96,150 shares · last 3 months, Aug 3, 2026 – Nov 3, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:GYRE · Home | $4.44 USD | -0.29 (-6.1%) | 239,505 | $4.61 | $4.713 | $4.40 | $4.73 | Close on Nov 3, 2026 |
| Frankfurt:L9S | €5.75 EUR | +0.30 (+5.5%) | — | €5.75 | €5.75 | €5.75 | €5.45 | Close on Oct 30, 2026 |
Daily closes
Last 3 months, Aug 3, 2026 – Nov 3, 2026 · NASDAQ:GYRE · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $4.44 | -0.29 | -6.1% | $4.61 | $4.713 | $4.40 | 239,505 | |
| $4.73 | +0.17 | +3.7% | $4.765 | $5.111 | $4.265 | 389,772 | |
| $4.56 | -1.85 | -28.9% | $6.27 | $6.30 | $4.52 | 394,100 | |
| $6.41 | -0.68 | -9.6% | $6.86 | $6.99 | $6.37 | 185,300 | |
| $7.09 | +0.56 | +8.6% | $6.53 | $7.10 | $6.33 | 125,100 | |
| $6.53 | +0.46 | +7.6% | $6.10 | $6.55 | $6.01 | 126,400 | |
| $6.07 | +0.22 | +3.8% | $5.77 | $6.10 | $5.77 | 93,400 | |
| $5.85 | -0.01 | -0.2% | $5.85 | $5.90 | $5.70 | 151,500 | |
| $5.86 | -0.04 | -0.7% | $5.91 | $6.00 | $5.80 | 66,600 | |
| $5.90 | -0.27 | -4.4% | $6.21 | $6.21 | $5.86 | 131,400 | |
| $6.17 | +0.08 | +1.3% | $6.08 | $6.34 | $6.08 | 242,100 | |
| $6.09 | +0.01 | +0.2% | $6.10 | $6.24 | $6.05 | 119,200 | |
| $6.08 | -0.32 | -5.0% | $6.41 | $6.43 | $6.04 | 142,900 | |
| $6.40 | -0.07 | -1.1% | $6.51 | $6.65 | $6.40 | 108,800 | |
| $6.47 | -0.24 | -3.6% | $6.70 | $6.75 | $6.44 | 162,800 | |
| $6.71 | -0.16 | -2.3% | $6.89 | $6.92 | $6.71 | 85,100 | |
| $6.87 | -0.17 | -2.4% | $7.00 | $7.07 | $6.85 | 82,000 | |
| $7.04 | +0.28 | +4.1% | $6.80 | $7.09 | $6.76 | 76,600 | |
| $6.76 | -0.28 | -4.0% | $7.04 | $7.04 | $6.74 | 82,800 | |
| $7.04 | -0.04 | -0.6% | $7.03 | $7.15 | $6.99 | 99,200 | |
| $7.08 | -0.27 | -3.7% | $7.42 | $7.42 | $7.01 | 134,000 | |
| $7.35 | +0.24 | +3.4% | $7.17 | $7.43 | $7.09 | 181,500 | |
| $7.11 | +0.11 | +1.6% | $7.09 | $7.35 | $7.08 | 163,700 | |
| $7.00 | -0.33 | -4.5% | $7.35 | $7.38 | $7.00 | 140,000 | |
| $7.33 | +0.01 | +0.1% | $7.32 | $7.38 | $7.13 | 159,800 | |
| $7.32 | -0.17 | -2.3% | $7.52 | $7.74 | $7.31 | 115,100 | |
| $7.49 | +0.14 | +1.9% | $7.35 | $7.56 | $7.30 | 137,000 | |
| $7.35 | +0.02 | +0.3% | $7.39 | $7.42 | $7.13 | 134,800 | |
| $7.33 | -0.07 | -0.9% | $7.40 | $7.44 | $6.81 | 327,700 | |
| $7.40 | -0.09 | -1.2% | $7.49 | $7.50 | $7.04 | 164,500 | |
| $7.49 | +0.06 | +0.8% | $7.40 | $7.61 | $7.26 | 227,000 | |
| $7.43 | -0.12 | -1.6% | $7.55 | $7.57 | $7.21 | 364,900 | |
| $7.55 | +0.37 | +5.2% | $7.12 | $7.56 | $7.10 | 1,203,600 | |
| $7.18 | +0.48 | +7.2% | $6.80 | $7.20 | $6.80 | 143,200 | |
| $6.70 | +0.01 | +0.1% | $6.70 | $6.86 | $6.59 | 126,400 | |
| $6.69 | 0.00 | 0.0% | $6.69 | $6.72 | $6.46 | 97,800 | |
| $6.69 | -0.04 | -0.6% | $6.82 | $7.04 | $6.69 | 104,100 | |
| $6.73 | -0.01 | -0.1% | $6.86 | $6.95 | $6.73 | 69,800 | |
| $6.74 | -0.21 | -3.0% | $6.93 | $6.96 | $6.74 | 83,100 | |
| $6.95 | -0.22 | -3.1% | $7.17 | $7.27 | $6.94 | 104,700 | |
| $7.17 | +0.31 | +4.5% | $6.85 | $7.20 | $6.85 | 239,900 | |
| $6.86 | +0.42 | +6.5% | $6.44 | $6.89 | $6.41 | 56,000 | |
| $6.44 | +0.08 | +1.3% | $6.37 | $6.54 | $6.36 | 41,200 | |
| $6.36 | -0.11 | -1.7% | $6.41 | $6.67 | $6.34 | 58,100 | |
| $6.47 | -0.10 | -1.5% | $6.51 | $6.57 | $6.32 | 54,500 | |
| $6.57 | -0.02 | -0.3% | $6.60 | $6.64 | $6.43 | 41,700 | |
| $6.59 | -0.09 | -1.3% | $6.70 | $6.70 | $6.54 | 43,200 | |
| $6.68 | +0.03 | +0.5% | $6.63 | $6.77 | $6.63 | 25,300 | |
| $6.65 | -0.03 | -0.4% | $6.71 | $6.81 | $6.60 | 38,800 | |
| $6.68 | +0.24 | +3.7% | $6.53 | $6.72 | $6.49 | 44,500 | |
| $6.44 | -0.47 | -6.8% | $6.89 | $6.89 | $6.42 | 53,300 | |
| $6.91 | -0.11 | -1.6% | $7.08 | $7.12 | $6.86 | 66,000 | |
| $7.02 | -0.13 | -1.8% | $7.15 | $7.29 | $6.77 | 55,100 | |
| $7.15 | +0.17 | +2.4% | $7.06 | $7.27 | $7.03 | 87,800 | |
| $6.98 | +0.17 | +2.5% | $6.73 | $7.00 | $6.72 | 49,600 | |
| $6.81 | +0.13 | +1.9% | $6.62 | $6.83 | $6.55 | 47,600 | |
| $6.68 | +0.14 | +2.1% | $6.55 | $6.73 | $6.47 | 52,700 | |
| $6.54 | -0.12 | -1.8% | $6.70 | $6.77 | $6.44 | 49,000 | |
| $6.66 | +0.02 | +0.3% | $6.68 | $6.99 | $6.62 | 94,500 | |
| $6.64 | -0.08 | -1.2% | $6.76 | $6.93 | $6.58 | 50,200 | |
| $6.72 | +0.05 | +0.7% | $6.67 | $6.80 | $6.31 | 53,200 | |
| $6.67 | +0.27 | +4.2% | $6.41 | $6.69 | $6.28 | 68,000 | |
| $6.40 | +0.17 | +2.7% | $6.28 | $6.51 | $6.21 | 49,100 | |
| $6.23 | +0.08 | +1.3% | $6.19 | $6.27 | $6.10 | 35,300 | |
| $6.15 | +0.04 | +0.7% | $6.11 | $6.46 | $6.11 | 63,200 | |
| $6.11 | +0.36 | +6.3% | $5.80 | $6.13 | $5.80 | 53,700 |
- Ticker
- Lang & Schwarz:A3EE5F
- Asset type
- Stock
- Exchange
- Lang & Schwarz
- Currency
- EUR
What changed lately
Latest news release · Sep 3, 2026
Gyre Therapeutics to Participate in Upcoming September Investor Conferences
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 26 slides
Latest news
Gyre Therapeutics to Participate in Upcoming September Investor Conferences
Sep 3, 2026
Closed $6.44 (+1.3%) on Sep 3, 2026
Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update
Aug 7, 2026
Closed $6.67 (+4.2%) on Aug 7, 2026
Gyre Therapeutics Appoints Three New Members to its Board of Directors
Jul 16, 2026
Closed $6.05 (-5.8%) on Jul 17, 2026
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
May 12, 2026
Closed $7.28 (-0.3%) on May 13, 2026
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
May 7, 2026
Closed $7.07 (-12.1%) on May 7, 2026
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S. and China-based Fully Integrated Biopharmaceutical Company
May 5, 2026
Closed $8.04 (+3.3%) on May 6, 2026
Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment
Mar 17, 2026
Closed $7.65 (+2.0%) on Mar 17, 2026
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Mar 12, 2026
Closed $7.81 (-6.2%) on Mar 12, 2026
Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline
Mar 2, 2026
Closed $8.76 (+6.3%) on Mar 2, 2026
Decks
Investor Presentation (September 2026)
Investor deck · 26 slides · September 2026
Investor Presentation (August 2026)
Investor deck · 44 slides · Aug 26, 2026
Investor Presentation (June 2026)
Investor deck · 42 slides · Jun 2, 2026
Investor Presentation (May 2026)
Investor deck · 21 slides · May 14, 2026
Gyre Therapeutics, Inc. on 6ix
- News releases
- 12 in the last 12 months · 128 in all · newest Sep 3, 2026 · oldest 2019
- Decks
- 9 decks · latest September 2026
Where Gyre Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:GYRE · Home listing | NASDAQ | United States | USD |
| LS Exchange:A3EE5F | LS Exchange | Germany | EUR |
| Lang & Schwarz:A3EE5F · This page | Lang & Schwarz | Germany | EUR |
| BOATS:GYRE | BOATS | United States | USD |
| Dusseldorf:L9S | Dusseldorf | Germany | EUR |
| Frankfurt:L9S | Frankfurt | Germany | EUR |
| Stuttgart:L9S | Stuttgart | Germany | EUR |
| Tradegate:L9S | Tradegate | Germany | EUR |
| gettex:L9S | gettex | Germany | EUR |
Log in to ask 6ix AI your own questions about Gyre Therapeutics, Inc.